UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware13-5315170

(State of Incorporation)(I.R.S. Employer Identification No.)

66 Hudson Boulevard East, New York, New York 10001-2192

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Stock, $0.05 par valuePFENew York Stock Exchange

1.000% Notes due 2027PFE27New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes Nox

At July 31, 2024, 5,666,695,064 shares of the issuer s voting common stock were outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Comprehensive Income/(Loss)

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Equity

Condensed Consolidated Statements of Cash Flows

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

39

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

60

Item 4.

Controls and Procedures

60

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

60

Item 1A.

Risk Factors

60

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

60

Item 3.

Defaults Upon Senior SecuritiesN/A

Item 4.

Mine Safety DisclosuresN/A

Item 5.

Other Information60

Item 6.

Exhibits

61

Signature

61

N/A = Not Applicable

DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 26, 2024 and May 28, 2023, and for U.S. subsidiaries is as of and for the three and six months ended June 30, 2024 and July 2, 2023. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2023 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:

2023 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2023

AbbVie

AbbVie Inc.

ALKanaplastic lymphoma kinase

Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ATTR-CMtransthyretin amyloid cardiomyopathy

Bain Capital

Bain Capital Private Equity and Bain Capital Life Sciences

BiohavenBiohaven Pharmaceutical Holding Company Limited

BioNTechBioNTech SE

BiopharmaGlobal Biopharmaceuticals Business

BMSBristol-Myers Squibb Company

BODBoard of Directors

CDCU.S. Centers for Disease Control and Prevention

Cerevel or Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc.

Comirnaty*Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; Comirnaty Omicron XBB.1.5; and Comirnaty JN.1.

COVID-19novel coronavirus disease of 2019

Developed MarketsIncludes, but is not limited to, the following markets: Western Europe, Japan, Canada, Central Europe, Australia, Scandinavian countries, South Korea, the Balkans, New Zealand and Finland

DMD

Duchenne muscular dystrophy

EMAEuropean Medicines Agency

Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, the Middle East, certain Eastern European countries and Turkey

EPS

earnings per share

ESGEnvironmental, Social and Governance

EUEuropean Union

EUAemergency use authorization

Exchange ActSecurities Exchange Act of 1934, as amended

FASBFinancial Accounting Standards Board

FDAU.S. Food and Drug Administration

Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024

GAAPGenerally Accepted Accounting Principles

GSKGSK plc

HaleonHaleon plc

HIPAAHealth Insurance Portability and Accountability Act of 1996

HospiraHospira, Inc.

HRR

homologous recombination repair

IPR&Din-process research and development

IRAInflation Reduction Act of 2022

IRSU.S. Internal Revenue Service

JVjoint venture

KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

mCRCmetastatic colorectal cancer

mCRPCmetastatic castration-resistant prostate cancer

mCSPCmetastatic castration-sensitive prostate cancer

MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations

MDLMulti-District Litigation

MeridianMeridian Medical Technologies, Inc.

Moody s

Moody s Investors Service

mRNAmessenger ribonucleic acid

MylanMylan N.V.

NDA

New Drug Application

NimbusNimbus Therapeutics, LLC

nmCRPCnon-metastatic castration-resistant prostate cancer

nmCSPC

non-metastatic castration-sensitive prostate cancer

NSCLCnon-small cell lung cancer

ODToral disintegrating tablet

ORD

Oncology Research and Development

OTCover-the-counter

Paxlovid*an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)

PC1Pfizer CentreOne

PharmaciaPharmacia LLC (formerly Pharmacia Corporation)

PP&E

Property, plant and equipment

PRD

Pfizer Research and Development

Prevnar familyIncludes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)

PsApsoriatic arthritis

QTDQuarter-to-date or three months ended

RArheumatoid arthritis

RCCrenal cell carcinoma

R&Dresearch and development

RSVrespiratory syncytial virus

S&PStandard & Poor s

SeagenSeagen Inc. and its subsidiaries

SECU.S. Securities and Exchange Commission

Takeda

Takeda Pharmaceutical Company Limited

UCulcerative colitis

U.K.United Kingdom

Upjohn BusinessPfizer s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris

U.S.United States

ViatrisViatris Inc.

ViiVViiV Healthcare Limited

Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac

YTDYear-to-date or six months ended

*The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) and certain uses of Paxlovid have not been approved or licensed by the FDA. The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has been authorized for emergency use by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months through 11 years of age. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.

This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.

The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X (formerly known as Twitter) accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.

Certain of the products and product candidates discussed in this Form 10-Q are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months EndedSix Months Ended

(MILLIONS, EXCEPT PER SHARE DATA)June 30,

2024July 2,

2023June 30,

2024July 2,

2023

Revenues:

Product revenues(a)

$10,871 $10,766 $23,314 $26,988

Alliance revenues(a)

2,067 1,967 4,240 4,028

Royalty revenues(a)

345 273 608 477

Total revenues13,283 13,007 28,162 31,492

Costs and expenses:

Cost of sales(b)

3,300 3,237 6,679 8,122

Selling, informational and administrative expenses(b)

3,717 3,497 7,212 6,914

Research and development expenses(b)

2,696 2,648 5,189 5,153

Acquired in-process research and development expenses6 33 6 55

Amortization of intangible assets1,307 1,184 2,615 2,287

Restructuring charges and certain acquisition-related costs1,254 214 1,356 222

Other (income)/deductions net1,107 (75)1,787 200

Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)

(103)2,269 3,318 8,539

Provision/(benefit) for taxes on income/(loss)

(134)(71)159 644

Income from continuing operations31 2,340 3,159 7,895

Discontinued operations net of tax17 (2)12 (1)

Net income before allocation to noncontrolling interests48 2,338 3,171 7,894

Less: Net income attributable to noncontrolling interests7 11 15 24

Net income attributable to Pfizer Inc. common shareholders$41 $2,327 $3,156 $7,870

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders$0.01 $0.41 $0.56 $1.40

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders$0.01 $0.41 $0.56 $1.40

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders$0.01 $0.41 $0.55 $1.38

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders$0.01 $0.41 $0.55 $1.38

Weighted-average shares basic5,666 5,646 5,662 5,640

Weighted-average shares diluted5,696 5,713 5,696 5,720

(a)See Note 1A.

(b)Exclusive of amortization of intangible assets.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)

(UNAUDITED)

Three Months EndedSix Months Ended

(MILLIONS)June 30,

2024July 2,

2023June 30,

2024July 2,

2023

Net income before allocation to noncontrolling interests$48 $2,338 $3,171 $7,894

Foreign currency translation adjustments, net(70)242 70 343

Unrealized holding gains/(losses) on derivative financial instruments, net127 109 343 112

Reclassification adjustments for (gains)/losses included in net income(a)

(147)(163)(159)140

(21)(54)184 251

Unrealized holding gains/(losses) on available-for-sale securities, net(25)26 (77)113

Reclassification adjustments for (gains)/losses included in net income(b)

100 16 86 (493)

74 42 9 (379)

Reclassification adjustments related to amortization of prior service costs and other, net(28)(30)(56)(59)

Reclassification adjustments related to curtailments of prior service costs and other, net (7) (12)

(28)(37)(56)(72)

Other comprehensive income/(loss), before tax(44)193 207 143

Tax provision/(benefit) on other comprehensive income/(loss)22 9 76 (53)

Other comprehensive income/(loss) before allocation to noncontrolling interests$(67)$184 $131 $196

Comprehensive income/(loss) before allocation to noncontrolling interests$(19)$2,522 $3,302 $8,091

Less: Comprehensive income/(loss) attributable to noncontrolling interests(2)8 1 18

Comprehensive income/(loss) attributable to Pfizer Inc.$(17)$2,514 $3,302 $8,072

(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.

(b)Reclassified into Other (income)/deductions net.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS)June 30,

2024December 31, 2023

(Unaudited)

Assets

Cash and cash equivalents$1,052 $2,853

Short-term investments6,048 9,837

Trade accounts receivable, less allowance for doubtful accounts: 2024 $468; 2023 $470

11,393 11,566

Inventories11,447 10,189

Current tax assets3,694 3,978

Other current assets4,190 4,911

Total current assets37,825 43,333

Equity-method investments8,029 11,637

Long-term investments3,119 3,731

Property, plant and equipment, less accumulated depreciation: 2024 $16,572; 2023 $16,045

18,957 18,940

Identifiable intangible assets61,240 64,900

Goodwill68,445 67,783

Noncurrent deferred tax assets and other noncurrent tax assets7,867 3,706

Other noncurrent assets10,710 12,471

Total assets$216,193 $226,501

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2024 $3,745; 2023 $2,254

$11,944 $10,350

Trade accounts payable5,106 6,710

Dividends payable2,380 2,372

Income taxes payable2,884 2,349

Accrued compensation and related items2,566 2,776

Deferred revenues2,528 2,700

Other current liabilities16,410 20,537

Total current liabilities43,819 47,794

Long-term debt57,506 61,538

Pension and postretirement benefit obligations2,040 2,167

Noncurrent deferred tax liabilities2,227 640

Other taxes payable6,532 8,534

Other noncurrent liabilities16,095 16,539

Total liabilities128,218 137,213

Commitments and Contingencies

Common stock480 478

Additional paid-in capital93,197 92,631

Treasury stock(114,757)(114,487)

Retained earnings116,596 118,353

Accumulated other comprehensive loss(7,816)(7,961)

Total Pfizer Inc. shareholders equity87,700 89,014

Equity attributable to noncontrolling interests275 274

Total equity87,975 89,288

Total liabilities and equity$216,193 $226,501

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, March 31, 20249,592 $480 $92,997 (3,925)$(114,755)$121,318 $(7,758)$92,282 $276 $92,558

Net income/(loss)

41 41 7 48

Other comprehensive income/(loss), net of tax

(58)(58)(9)(67)

Cash dividends declared, per share: $0.84

Common stock(4,760)(4,760)(4,760)

Share-based payment transactions 200 (2)(2)196 196

Other

Balance, June 30, 20249,592 $480 $93,197 (3,925)$(114,757)$116,596 $(7,816)$87,700 $275 $87,975

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, April 2, 20239,560 $478 $92,153 (3,915)$(114,473)$131,101 $(8,289)$100,970 $266 $101,236

Net income/(loss)

2,327 2,327 11 2,338

Other comprehensive income/(loss), net of tax187 187 (3)184

Cash dividends declared, per share: $0.82

Common stock (4,630)(4,630)(4,630)

Share-based payment transactions1 176 (8)(4)164 164

Other

Balance, July 2, 20239,561 $478 $92,329 (3,916)$(114,482)$128,796 $(8,102)$99,019 $274 $99,293

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20249,562 $478 $92,631 (3,916)$(114,487)$118,353 $(7,961)$89,014 $274 $89,288

Net income

3,156 3,156 15 3,171

Other comprehensive income/(loss), net of tax145 145 (14)131

Cash dividends declared, per share: $0.84

Common stock(4,760)(4,760)(4,760)

Share-based payment transactions30 1 566 (10)(270)(153)144 144

Other

Balance, June 30, 20249,592 $480 $93,197 (3,925)$(114,757)$116,596 $(7,816)$87,700 $275 $87,975

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20239,519 $476 $91,802 (3,903)$(113,969)$125,656 $(8,304)$95,661 $256 $95,916

Net income

7,870 7,870 24 7,894

Other comprehensive income/(loss), net of tax202 202 (6)196

Cash dividends declared, per share: $0.82

Common stock (4,630)(4,630)(4,630)

Share-based payment transactions42 2 527 (12)(512)(101)(85)(85)

Other

Balance, July 2, 20239,561 $478 $92,329 (3,916)$(114,482)$128,796 $(8,102)$99,019 $274 $99,293

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(MILLIONS)June 30,

2024July 2,

2023

Operating Activities

Net income before allocation to noncontrolling interests$3,171 $7,894

Discontinued operations net of tax12 (1)

Net income from continuing operations before allocation to noncontrolling interests3,159 7,895

Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:

Depreciation and amortization3,467 3,060

Asset write-offs and impairments431 327

Deferred taxes(1,224)(1,471)

Share-based compensation expense426 253

Benefit plan contributions in excess of expense/income(338)(322)

Other adjustments, net260 (317)

Other changes in assets and liabilities, net of acquisitions and divestitures(6,871)(9,423)

Net cash provided by/(used in) operating activities(691)4

Investing Activities

Purchases of property, plant and equipment(1,341)(2,053)

Purchases of short-term investments(1,254)(21,006)

Proceeds from redemptions/sales of short-term investments1,712 12,594

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less3,538 (11,217)

Purchases of long-term investments(108)(92)

Proceeds from redemptions/sales of long-term investments312 172

Proceeds from partial sale of investment in Haleon(a)

3,491

Acquisition of business, net of cash acquired

(25)

Other investing activities, net(18)(543)

Net cash provided by/(used in) investing activities6,332 (22,170)

Financing Activities

Proceeds from short-term borrowings6,014 14

Payments on short-term borrowings(4,852)

Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less

(1,101)22

Proceeds from issuance of long-term debt 30,831

Payments on long-term debt(2,250)(1,269)

Cash dividends paid(4,752)(4,618)

Other financing activities, net(449)(576)

Net cash provided by/(used in) financing activities(7,390)24,403

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

(46)(7)

Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents(1,794)2,229

Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period2,917 468

Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,123 $2,698

Supplemental Cash Flow Information

Cash paid/(received) during the period for:

Income taxes

$2,686 $2,025

Interest paid

1,553 821

Interest rate hedges(2)31

(a) See Note 2B.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2023 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.

These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2023 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 26, 2024 and May 28, 2023, and for U.S. subsidiaries is as of and for the three and six months ended June 30, 2024 and July 2, 2023.

We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. See Note 13A.

We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for:

in the first quarter of 2024, we reclassified royalty income (substantially all of which is related to Biopharma) from Other (income)/deductions net and began presenting Royalty revenues as a separate line item within Total revenues in our consolidated statements of operations, and reclassified the associated royalty receivables from Other current assets to Trade accounts receivable, less allowance for doubtful accounts in our consolidated balance sheet;

in the fourth quarter of 2023, we began presenting Product revenues and Alliance revenues as separate line items within Total revenues in our consolidated statements of operations; and

segment reporting and geographic information in connection with the commercial reorganization that went into effect on January 1, 2024 (see Note 13).

Business development activities, including the December 2023 acquisition of Seagen, impacted financial results in the periods presented. See Note 2 below, as well as Notes 1A and 2 in our 2023 Form 10-K.

B. New Accounting Standard Adopted in 2024

On January 1, 2024, we adopted a new accounting standard which clarifies that contractual sale restrictions are not considered in measuring equity securities at fair value. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.

C. Revenues and Trade Accounts Receivable

Customers Our prescription biopharmaceutical products, with the exception of Paxlovid in 2023, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sold Paxlovid globally to government agencies in 2023. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain products in our portfolio are subject to seasonality of demand and Paxlovid revenues trend with infection rates.

Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:

(MILLIONS)June 30,

2024December 31, 2023

Reserve against Trade accounts receivable, less allowance for doubtful accounts

$1,578 $1,770

Other current liabilities:

Accrued rebates6,726 5,546

Other accruals529 902

Other noncurrent liabilities

569 796

Total accrued rebates and other sales-related accruals$9,401 $9,014

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.

In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.

During the three and six months ended June 30, 2024 and July 2, 2023, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2023 Form 10-K.

Note 2. Acquisition and Equity-Method Investment

A. Acquisition

Seagen On December 14, 2023 (the acquisition date), we acquired Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 per share in cash. The total fair value of the consideration transferred was $44.2 billion ($43.4 billion, net of cash acquired). The combination of certain Pfizer and Seagen entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps.

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, including adjustments made in the first six months of 2024 (measurement period adjustments) with a corresponding change to goodwill. The estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as soon as possible but no later than one year from the acquisition date.

(MILLIONS)Amounts Recognized

as of Acquisition Date

(as previously reported as of December 31, 2023)

Measurement Period Adjustments(a)

Amounts Recognized as of Acquisition Date (as adjusted)

Working capital, excluding inventories

$736 $(184)$552

Inventories(b)

4,195 (891)3,304

Property, plant and equipment524 (233)291

Identifiable intangible assets, excluding in-process research and development(c)

7,970 (575)7,395

In-process research and development20,800 (50)20,750

Other noncurrent assets174 (106)67

Net income tax accounts

(6,123)1,313 (4,810)

Other noncurrent liabilities(167)50 (117)

Total identifiable net assets28,108 (677)27,431

Goodwill16,126 677 16,803

Net assets acquired/total consideration transferred$44,234 $ $44,234

(a)The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

(b)As adjusted, comprised of $1.2 billion current inventories and $2.1 billion noncurrent inventories.

(c)As adjusted, comprised mainly of $6.9 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.

The measurement period adjustments did not have a material impact on our earnings.

The following items are subject to change:

Amounts for certain balances included in working capital (excluding inventories), and certain legal contingencies, pending receipt of certain information that could affect provisional amounts recorded. We do not believe any adjustments for legal contingencies will have a material impact on our consolidated financial statements.

Amounts for identifiable intangible assets, inventories, contractual commitments, PP&E, and operating lease right-of-use assets and liabilities, pending finalization of valuation efforts and the completion of certain physical inventory counts.

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Amounts for income tax assets, receivables and liabilities, pending the filing of Seagen s pre-acquisition tax returns and the receipt of information, including but not limited to that from taxing authorities, which may change certain estimates and assumptions used.

The following table provides unaudited U.S. GAAP supplemental pro forma information as if the acquisition of Seagen had occurred on January 1, 2022:

Unaudited Supplemental

Pro Forma Consolidated Results

Three Months EndedSix Months Ended

(MILLIONS, EXCEPT PER SHARE DATA)July 2,

2023July 2,

2023

Revenues$13,611 $32,616

Net income attributable to Pfizer Inc. common shareholders

1,389 6,040

Diluted earnings per share attributable to Pfizer Inc. common shareholders

0.24 1.06

The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company s results of operations would have been had the acquisition occurred on January 1, 2022, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma adjustments reflected here due to many factors.

The unaudited supplemental pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of the assets acquired and the liabilities assumed from Seagen. The historical U.S. GAAP financial information of Pfizer and Seagen was adjusted, primarily for the following pre-tax adjustments for the three and six months ended July 2, 2023:

Additional amortization expense of approximately $143 million and $285 million, respectively, related to the preliminary estimate of the fair value of identifiable intangible assets acquired.

Additional expense related to the preliminary estimate of the fair value adjustment to acquisition-date inventory estimated to have been sold of approximately $224 million and $449 million, respectively.

Additional estimated interest expense of approximately $303 million and $791 million, respectively, related to the debt issued by Pfizer and the commercial paper borrowings to partially finance the acquisition.

Elimination of interest income of approximately $263 million and $330 million, respectively, associated with money market funds under the assumption that a portion of these funds would have been liquidated to partially fund the acquisition.

The above adjustments were then adjusted for the applicable tax impact using an estimated weighted-average statutory tax rate applied to the applicable pro forma adjustments.

B. Equity-Method Investment

Haleon We owned 32% of Haleon as of December 31, 2023. In March 2024, we sold approximately 30% of our investment in Haleon through the sale of 791 million ordinary shares in a global public offering, and the sale of 102 million ordinary shares directly to Haleon for total consideration of $3.5 billion. We recognized a gain on the sale of our Haleon shares of $150 million during the first quarter of 2024 in Other (income)/deductions net (see Note 4). After the share sale, we owned approximately 23% of the outstanding voting shares of Haleon as of June 30, 2024.

The fair value of our investment in Haleon as of June 30, 2024, based on quoted market prices of Haleon stock, was $8.4 billion. Haleon is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. We record our share of earnings from Haleon on a quarterly basis on a one-quarter lag in Other (income)/deductions net.

12

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table summarizes the change in the carrying value of our investment in Haleon:

Three Months EndedSix Months Ended

(MILLIONS)June 30,

2024July 2,

2023June 30,

2024July 2,

2023

Beginning carrying value reported in Equity-method investments

$7,922 $10,980 $11,451 $10,824

Carrying value of shares sold

(3,312)

Dividends

(157)(88)(157)(88)

Currency translation adjustments and other(a)

1 185 (130)274

Basis difference adjustments and amortization(b), (c)

(1) (101)(1)

Pfizer share of Haleon investee capital transaction(b), (d)

(91) (91)

Pfizer share of Haleon earnings(b)

121 151 136 219

Ending carrying value reported in Equity-method investments

$7,796 $11,228 $7,796 $11,228

(a)See Note 6.

(b)Included in Other (income)/deductions net.

(c)Adjustments in the six months ended June 30, 2024 are associated with (i) the impact of Haleon s brand divestitures and impairments of intangible assets and (ii) changes in Haleon s tax rates on intangible asset-related deferred tax liabilities. See Note 4.

(d)Amounts for the three and six months ended June 30, 2024 relate to Pfizer s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024.

Summarized financial information for Haleon for the three and six months ending March 31, 2024, the most recent period available, and for the three and six months ending March 31, 2023, is as follows:

Three Months EndedSix Months Ended

(MILLIONS)March 31,

2024March 31,

2023March 31,

2024March 31,

2023

Net sales$3,699 $3,627 $7,133 $6,889

Cost of sales(1,370)(1,392)(2,966)(2,888)

Gross profit$2,329 $2,235 $4,167 $4,001

Income from continuing operations559 504 618 730

Net income559 504 618 730

Income attributable to shareholders536 473 583 684

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

A. Realigning our Cost Base Program

In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. We expect costs associated with this multi-year effort to continue primarily through 2024 and to total approximately $2.3 billion, primarily representing cash expenditures for severance and implementation costs, of which $1.7 billion is associated with our Biopharma segment. From the start of this program through June 30, 2024, we incurred costs under this program of $1.5 billion, of which $1.2 billion is associated with our Biopharma segment (substantially all of which represents restructuring charges).

B. Manufacturing Optimization Program

In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is focused on operational efficiencies and we expect costs for this first phase to total approximately $1.7 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. These costs will be recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026. From the start of this program through June 30, 2024, we incurred costs under this program of $1.3 billion, all of which is associated with our Biopharma segment and substantially all of which represents restructuring charges.

13

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

C. Key Activities

The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:

Three Months EndedSix Months Ended

(MILLIONS)June 30,

2024July 2,

2023June 30,

2024July 2,

2023

Restructuring charges/(credits):

Employee terminations$1,014 $96 $984 $61

Asset impairments41 15 66 4

Exit costs

49 27 63 29

Restructuring charges/(credits)(a)

1,104 138 1,114 94

Transaction costs(b)

8 5 8

Integration costs and other(c)

150 68 237 120

Restructuring charges and certain acquisition-related costs1,254 214 1,356 222

Net periodic benefit costs/(credits) recorded in Other (income)/deductions net

2 (2)5 (7)

Additional depreciation asset restructuring recorded in our condensed consolidated statements of operations as follows(d):

Cost of sales1 4 5 22

Selling, informational and administrative expenses3 3

Total additional depreciation asset restructuring

4 4 8 23

Implementation costs recorded in our condensed consolidated statements of operations as follows(e):

Cost of sales49 13 65 27

Selling, informational and administrative expenses36 67 65 126

Research and development expenses20 19 33 30

Total implementation costs105 98 163 183

Total costs associated with acquisitions and cost-reduction/productivity initiatives$1,364 $313 $1,532 $420

(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.1 billion for both the three and six months ended June 30, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program for both periods presented and credits of $113 million for the three months and $199 million for the six months ended June 30, 2024 for our Realigning our Cost Base Program). Amounts associated with our Biopharma segment for the three and six months ended July 2, 2023 were not material.

(b)Represents external costs for banking, legal, accounting and other similar services.

(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.

(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

The following summarizes the components and changes in restructuring accruals:

(MILLIONS)Employee

Termination

CostsAsset

Impairment

ChargesExit CostsAccrual

Balance, December 31, 2023(a)

$1,978 $ $11 $1,988

Provision/(credit)984 66 63 1,114

Utilization and other(b)

(592)(66)(45)(703)

Balance, June 30, 2024(c)

$2,370 $ $29 $2,399

(a)Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).

(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.

(c)Included in Other current liabilities ($1.0 billion) and Other noncurrent liabilities ($1.4 billion).

14

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 4. Other (Income)/Deductions Net

Components of Other (income)/deductions net include:

Three Months EndedSix Months Ended

(MILLIONS)June 30,

2024July 2,

2023June 30,

2024July 2,

2023

Interest income$(130)$(316)$(259)$(493)

Interest expense778 508 1,568 826

Net interest expense(a)

648 192 1,310 333

Net (gains)/losses recognized during the period on equity securities

342 (135)317 316

Income from collaborations, out-licensing arrangements and sales of compound/product rights(22)(7)(24)(74)

Net periodic benefit costs/(credits) other than service costs(106)(88)(209)(168)

Certain legal matters, net(b)

169 139 377 175

Certain asset impairments(c)

240 349 264

Haleon equity method (income)/loss(d)

(40)(156)48 (224)

Other, net(e)

(124)(20)(381)(423)

Other (income)/deductions net$1,107 $(75)$1,787 $200

(a)The increase in net interest expense in the second quarter and first six months of 2024 reflects (i) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as $8 billion of commercial paper issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen and (ii) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023.

(b)The second quarter and first six months of 2024 primarily include certain product liability expenses related to products discontinued and/or divested by Pfizer. The second quarter and first six months of 2023 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.

(c)The second quarter and first six months of 2024 include a $240 million intangible asset impairment charge, associated with our Biopharma segment that represents IPR&D related to a Phase 3 study for the treatment of DMD, which reflects unfavorable clinical trial results. The first six months of 2023 primarily represented intangible asset impairment charges, including (i) $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts, and (ii) $120 million associated with our Biopharma segment resulting from the discontinuation of a study related to an out-licensed IPR&D asset for the treatment of prostate cancer.

(d)See Note 2B.

(e)The second quarter of 2024 primarily includes, among other things, dividend income of $74 million from our investment in ViiV. The first six months of 2024 includes, among other things, a $150 million gain on the partial sale of our investment in Haleon and dividend income of $135 million from our investment in ViiV. The first six months of 2023 primarily included, among other things, dividend income of $211 million from our investment in Nimbus resulting from Takeda s acquisition of Nimbus s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary, and $183 million from our investment in ViiV.

Additional information about the intangible assets that were impaired during 2024 follows:

Six Months Ended

Fair Value(a)

June 30, 2024

(MILLIONS)AmountLevel 1Level 2Level 3Impairment

Intangible assets IPR&D(b)

$ $ $ $240

Intangible assets Developed technology rights(b)

102 102 109

Total

$102 $ $ $102 $349

(a)The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also Note 1E in our 2023 Form 10-K.

(b)Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Note 5. Tax Matters

A. Taxes on Income from Continuing Operations

Our effective tax rate for continuing operations was 130.2% for the second quarter of 2024, compared to (3.1)% for the second quarter of 2023, and was 4.8% for the first six months of 2024, compared to 7.5% for the first six months of 2023. The increase

15

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

in the effective tax rate for the second quarter of 2024, compared to the second quarter of 2023, was primarily due to the non-recurrence of tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years in the second quarter of 2023, partially offset by a favorable change in the jurisdictional mix of earnings in the second quarter of 2024.

We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The sixth annual installment was paid by its April 15, 2024 due date. The seventh annual installment is due April 15, 2025 and is reported in current Income taxes payable as of June 30, 2024. The remaining liability is reported in noncurrent Other taxes payable. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.

For the year ended December 31, 2023, our cash paid for income taxes, net of refunds, was $3.1 billion, of which $1.9 billion was paid in the U.S.

B. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.

The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, tax years 2016-2018 are under audit. Tax years 2019-2024 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2012.

See Note 5D in our 2023 Form 10-K.

C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)

Components of Tax provision/(benefit) on other comprehensive income/(loss) include:

Three Months EndedSix Months Ended

(MILLIONS)June 30,

2024July 2,

2023June 30,

2024July 2,

2023

Foreign currency translation adjustments, net(a)

$18 $20 $42 $(5)

Unrealized holding gains/(losses) on derivative financial instruments, net26 25 70 28

Reclassification adjustments for (gains)/losses included in net income

(23)(33)(26)(12)

3 (8)44 16

Unrealized holding gains/(losses) on available-for-sale securities, net(3)3 (9)14

Reclassification adjustments for (gains)/losses included in net income

12 2 11 (62)

9 5 1 (47)

Reclassification adjustments related to amortization of prior service costs and other, net(9)(7)(13)(14)

Reclassification adjustments related to curtailments of prior service costs and other, net1 (1)1 (3)

(7)(8)(12)(17)

Tax provision/(benefit) on other comprehensive income/(loss)$22 $9 $76 $(53)

(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.

16

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests

The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:

Net Unrealized Gains/(Losses)Benefit Plans

(MILLIONS)Foreign Currency Translation Adjustments(a)

Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)

Balance, December 31, 2023

$(7,863)$(217)$(9)$128 $(7,961)

Other comprehensive income/(loss)(b)

41 140 8 (44)145

Balance, June 30, 2024$(7,822)$(77)$(1)$84 $(7,816)

(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.

(b)Foreign currency translation adjustments include net gains related to the impact of our net investment hedging program and net losses related to our equity-method investment in Haleon (see Note 2B).

17

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Financial Instruments

A. Fair Value Measurements

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:

June 30, 2024December 31, 2023

(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2

Financial assets:

Short-term investments

Equity securities with readily determinable fair values:

Money market funds$975 $ $975 $5,124 $ $5,124

Available-for-sale debt securities:

Government and agency non-U.S.

1,120 1,120 817 817

Government and agency U.S.

2,073 2,073 2,601 2,601

Corporate and other

1,208 1,208 982 982

4,401 4,401 4,400 4,400

Total short-term investments5,376 5,376 9,524 9,524

Other current assets

Derivative assets:

Foreign exchange contracts

421 421 298 298

Total other current assets421 421 298 298

Long-term investments

Equity securities with readily determinable fair values(a)

2,210 2,210 2,779 2,772 7

Available-for-sale debt securities:

Government and agency non-U.S.

63 63 124 124

Corporate and other

6 6 26 26

69 69 150 150

Total long-term investments2,280 2,210 70 2,929 2,772 156

Other noncurrent assets

Derivative assets:

Interest rate contracts

19 19 144 144

Foreign exchange contracts

354 354 258 258

Total derivative assets374 374 402 402

Insurance contracts(b)

872 872 790 790

Total other noncurrent assets1,246 1,246 1,191 1,191

Total assets$9,322 $2,210 $7,112 $13,943 $2,772 $11,170

Financial liabilities:

Other current liabilities

Derivative liabilities:

Interest rate contracts$33 $ $33 $16 $ $16

Foreign exchange contracts

139 139 404 404

Total other current liabilities172 172 420 420

Other noncurrent liabilities

Derivative liabilities:

Interest rate contracts375 375 275 275

Foreign exchange contracts

682 682 725 725

Total other noncurrent liabilities1,056 1,056 1,000 1,000

Total liabilities$1,228 $ $1,228 $1,420 $ $1,420

(a)Long-term equity securities of $119 million as of June 30, 2024 and $130 million as of December 31, 2023 were held in restricted trusts for U.S. non-qualified employee benefit plans.

(b)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).

Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion, was $58 billion as of June 30, 2024 and $62 billion as of December 31, 2023. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $54 billion as of June 30, 2024 and $61 billion as of December 31, 2023.